Tools

Julio César Delgado-Arce1, Fabiola Alejandra Becerra-Arciniega2, Elizabeth Escamilla-Chávez1, Hector Sebastián VelascoTorres1, Pablo David Guerrero-Suarez1, Jaime Jesús Mártinez-Anda3
  1. Department of Neurosurgery, Centro Médico Arturo Montiel Rojas, Instituto de Seguridad Social del Estado de México y Municipios, México-Toluca, Metepec,
  2. Department of Radiology, Centro Médico Arturo Montiel Rojas, Instituto de Seguridad Social del Estado de México y Municipios, México-Toluca, Metepec,
  3. Department of Neurological Center, ABC Medical Center, Tlaxcala Santa Fe, Mexico.

Correspondence Address:
Julio César Delgado-Arce, Department of Neurosurgery, Centro Médico Arturo Montiel Rojas, Instituto de Seguridad Social del Estado de México y Municipios, México-Toluca, Metepec, Mexico.

DOI:10.25259/SNI_668_2022

Copyright: © 2022 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Julio César Delgado-Arce1, Fabiola Alejandra Becerra-Arciniega2, Elizabeth Escamilla-Chávez1, Hector Sebastián VelascoTorres1, Pablo David Guerrero-Suarez1, Jaime Jesús Mártinez-Anda3. Mycotic clival osteomyelitis secondary to immunosuppression by SARS-CoV-2. 07-Oct-2022;13:459

How to cite this URL: Julio César Delgado-Arce1, Fabiola Alejandra Becerra-Arciniega2, Elizabeth Escamilla-Chávez1, Hector Sebastián VelascoTorres1, Pablo David Guerrero-Suarez1, Jaime Jesús Mártinez-Anda3. Mycotic clival osteomyelitis secondary to immunosuppression by SARS-CoV-2. 07-Oct-2022;13:459. Available from: https://surgicalneurologyint.com/surgicalint-articles/11919/

Date of Submission
24-Jul-2022

Date of Acceptance
20-Sep-2022

Date of Web Publication
07-Oct-2022

Abstract

Background: During the past 2 years, the use of systemic corticosteroids has increased due to COVID-19 atypical pneumonia management. Similarly, an increase in mycotic infection cases has been reported during the same period as a consequence of immunosuppression caused by corticosteroid overuse. Mycotic clival osteomyelitis is a rare clinical entity which presumably has increased its incidence during the pandemic.

Case Description: A 52-year-old woman who presented persistent headaches and unexplained weight loss after being hospitalized due to COVID-19 pneumonia treated with intravenous corticosteroids. Head computed tomography and magnetic resonance imaging showed extensive osteomyelitis at the clival region with no brain parenchyma involvement. Surgical excision through navigation-guided transnasal transclival endoscopic extended approach was performed for surgical debridement. Histopathological analysis revealed angulated hyphae, suggestive of Aspergillosis. Systemic antifungal treatment was administered for 30 consecutive days. Afterward, she was discharged without any remarkable neurological findings, reassessed during follow-up.

Conclusion: The COVID-19 pandemic has had an effect on the reemergence of mycotic infections due to corticosteroid immunosuppression. Clival osteomyelitis secondary to mycotic infection is an exclusion diagnosis that we encourage to be highly suspected within the persisting COVID-19 pandemic.

Keywords: Aspergillosis, COVID-19, Osteomyelitis

INTRODUCTION

Since the end of 2019, COVID-19 has infected more than 500 million people, with more than 6 million deaths up to date.[ 12 ] Incidence of mycotic infections has increased on account of the COVID-19 pandemic, the use of corticosteroids in the context of atypical COVID-19 pneumonia, and type 2 diabetes as a comorbidity.[ 13 ] The clinical scenario, where severe COVID-19 and type 2 diabetes converge, is optimal conditions for mycotic proliferation to develop in an immunocompromised host.[ 10 ]

Skull base osteomyelitis (SBO) is a rare, yet potentially treatable disease. Usually, the microorganisms involved are Staphylococcus aureus, and the most prevalent mycotic agent is Aspergillosis fumigatus.[ 14 ] Within the still present COVID-19 pandemic, the coexistence of SARS-CoV-2 and Mucormycosis (also known as black fungus) has been reported, infecting nasal and orbital bone structures, occasionally with an extension to skull base brain parenchyma.[ 8 ] We present the case of an Aspergillosis infection with clival bone extension, within the context of a previously treated COVID-19 infection.

CLINICAL CASE PRESENTATION

A 52-year-old female with a previous medical history of hypertension in adherence to antihypertensive treatment (thiazide and angiotensin II receptor blocker), type 2 diabetes in adherence to Glargine insulin, and metformin treatment, arrived to the emergency room with ventilatory compromise and hypoxemia. SARS-CoV-2 infection was diagnosed with a positive PCR test, clinically classified as moderate COVID-19 due to fever, dyspnea, and hypoxemia, which required 18 days of hospitalization and management with intravenous corticosteroids (6 mg dexamethasone q. d.) as well as subcutaneous low-molecular-weight heparin (60 mg enoxaparin q. d.). Hospital discharge was decided after stable and favorable clinical evolution, with prescription of continuous supplementary oxygen (5 L/h), dose adjustment of antidiabetic drugs, with no further required changes or complications.

Two weeks after hospital discharge, she presents a mild headache (visual analog scale 4/10). A month after discharge, she presents malaise and an unexplained weight loss of 8 kg. During follow-up, neurologic examination was unremarkable and there was no further need of supplementary oxygen. Nevertheless, cephalgia and intermittent nasal constipation were the patient’s prevalent symptoms.

A head computed tomography (CT) scan was performed, which revealed a lesion within the paranasal sinuses. Bone window revealed demineralization with trabecular pattern, and cortical involvement of the walls of the ethmoid and sphenoid sinuses, pterygoid processes, turbinate bones, nasal septum, clivus, petrous apex, vomer, carotid foramina, greater wings of the sphenoid bone, frontal processes, orbital processes of frontal bone, and anterior and posterior clinoid processes, [ Figure 1 ].


Figure 1:

Axial computed tomography scan, bone window with osteomyelitis extension within the occipital bone base and the sphenoidal sinus.

 

Magnetic resonance imaging (MRI) of the skull base at the level of the clivus and the petrous apex showed soft tissues as isointense to muscle tissue in T1-weighted sequence and hyperintense in T2-weighted as well as in fluid-attenuated inversion recovery sequence, with gadolinium enhancement in fat-saturated contrast-enhanced T1-weighted (T1+C+FAT) sequence, [ Figure 2 ]. Loss of fat planes among soft tissue was identified with restriction in diffusion sequence, corroborated in apparent diffusion coefficient (ADC) sequence map, [ Figure 3 ].


Figure 2:

Axial magnetic resonance imaging demonstrating a hypointense lesion with sphenoid boy and clival bone involvement (a) infiltrating nasopharyngeal submucous tissue (b) with a hypointense appearance in T1 and T2 sequences. Gadolinium enhancement in T1 of sphenoid and clival bone tissue.

 

Figure 3:

Axial diffusion-weighted imaging with focal fluid along the anterior wall of the sphenoid sinus persisting hyperintensity, suggesting focal abscess.

 

Given the MRI findings, surgical excision through navigation-guided transnasal transclival endoscopic extended approach and later nasoseptal pediculated flap rotation was performed, [ Figure 4 ]. Transoperative findings showed sphenoidal rostrum lysis with extension to lateral recesses, clival, and sella turcica osteolysis, with no dural invasion. Surgical debridement was performed in a conventional manner, with no apparent complications. The patient was discharged 48 h postsurgery, with no clinical signs of transnasal fistula.


Figure 4:

Navigation-guided transnasal transclival endoscopic extended approach with clival drilling.

 

Microbiology and histopathological analysis revealed 90° angled hyphae suspicious of Aspergillosis, [ Figure 5 ]. A culture confirmation of the fungus was realized, with positive results to Aspergillus spp. Hospital readmission was suggested for antimicrobial treatment; intravenous fluconazole and liposomal amphotericin B treatment were prescribed for 30 days, which concluded with no further complications.


Figure 5:

Microphotography of histopathological bone tissue sample with hematoxylin and eosin staining. Numerous angled hyphae of Aspergillus spp. are identified (yellow arrow).

 

DISCUSSION

SBO is a rare entity with high risk of mortality, representing both a clinical and imaging diagnostic challenge. There are two categories of skull base osteomyelitis: typical and atypical (or central) osteomyelitis.[ 6 ]

Typical SBO is the most frequent type among these two. Most typical SBO cases present within diabetic and elder population, whose immunocompromise leads to external necrotizing otitis by Pseudomonas infection.[ 5 ] Atypical or central SBO invades the sphenoidal and occipital bones, with nonrelated previous otic infection.[ 11 ] S. aureus and Pseudomonas aeruginosa are some of the most frequently reported bacterial pathogens in atypical SBO. Likewise, A. fumigatus is the mycotic pathogen most frequently reported in the literature.[ 14 ] The known mechanism of skull base invasion by these microorganisms is through contiguous translocation through Santorini fissures and hematologic translocation through the venous plexus located within the temporal bone.[ 18 ] An established anatomical risk factor for clival osteomyelitis is a prominent navicular fossa, which is a known anatomical variant of clival morphology.[ 15 ]

Throughout the COVID-19 pandemic, clinical severity has been graded as asymptomatic, symptomatic, ventilatory compromise, severe ventilatory failure, and death. Within the context of COVID-19, bacterial and mycotic secondary infections are a clinical challenge due to its abrupt increase of morbidity and mortality.[ 19 ] Candidiasis and Aspergillosis were the most commonly reported fungi pathogens correlated to COVID-19 infection during the pandemic.[ 9 ] In addition, it has been also demonstrated that corticosteroids are an effective treatment as immune response modulators, resulting in a decrease in mortality in severe COVID-19 infection.[ 17 ] Nevertheless, the overuse of corticosteroids also conveys a higher risk of secondary opportunistic coinfections that may risk patient’s survival.[ 13 ]

Cephalgia and facial pain are symptoms reported in most SBO cases. However, several cases with cranial nerves affection (VI, IX, X, XI, and XII) have been reported.[ 16 ] Due to the ambiguous signs and symptoms that may be present, difficulties to reach a diagnosis are common, as well as the misdiagnosis of malignant skull base tumors in different imaging studies.

Radio imaging correlation with the clinical presentation is fundamental during the diagnosis approach of SBO. In general, the use of contrasted CT scan and gadolinium-enhanced MRI is fundamental. In complex cases, the use of functional studies may provide us useful bone metabolism data, such as positron emission tomography CT scan with technetium 99.[ 6 ]

When atypical SBO is present, it is important to evaluate key areas including the bony external auditory canal, mastoid process, temporomandibular joint, petrous apex, petro-occipital fissure, foramen lacerum, jugular foramen, and clivus, where most frequently the origin of disease is clival infection.[ 1 , 6 , 16 ]

CT scan is the gold standard imaging study for SBO. It is a helpful tool to evaluate the extent and severity of infection, as well as to assess cortical bone erosion or trabecular demineralization related to osteomyelitis.[ 6 , 11 , 16 ] There is often evidence of invasive sinusitis with cortical erosions of the paranasal sinuses, particularly the sphenoid or ethmoid sinuses, anterior clivus, and foramina of the central skull base.[ 6 , 16 ] Contrast-enhanced CT scan can be of additional benefit for the evaluation of vascular complications, including cavernous sinus thrombosis or stroke.[ 6 ]

MRI is complementary for soft-tissue analysis around the skull base and medullary cavity of the bone.[ 6 , 11 ] On T1-weighted sequence, the ill-defined soft issue demonstrates either hypo- or isointense signal of the muscle, causing fat plane obliteration. When osteomyelitis affects the bone marrow, there is loss of normal fat signal within the bone marrow space. Infiltration may precede edema and phlegmon, which are evidenced as hyperintensity in T2 sequence and heterogeneous enhancement in T1-weighted fat-saturated and contrast-enhanced sequences.[ 6 , 11 ] In severe osteomyelitis, bone marrow may progress from necrotic tissue into an abscess, producing a ring-enhanced lesion.[ 6 ] Diffusion restriction in nonenhanced fluid collections can help confirm an abscess. In addition, ADC sequence may allow distinction between SBO and neoplastic lesions.[ 6 ]

Nuclear medicine provides both functional and metabolic data of the osseous tissue, complementing for localization of skull base infection. Specifically, technetium 99m-methyl diphosphonate (Tc99m MDP) demonstrates a higher osteoblastic activity whenever an infectious process is present within the bone.[ 2 ]

Surgical debridement and antimycotic treatment are the standard therapy on invasive SBO caused by Aspergillosis.[ 3 ] The main objective of surgical treatment is to perform a safe and maximum debridement with posterior long-term antimycotic treatment.[ 4 ] In the previous decades, liposomal amphotericin B used to be the treatment of choice for invasive Aspergillosis.[ 7 ] Voriconazole, a second-generation triazole, has demonstrated a greater efficacy as treatment proposed for Aspergillosis. The previous studies have demonstrated an effective soft tissue and bone distribution of voriconazole, which is convenient due to bone, meningeal, and central nervous system damage held by invasive Aspergillosis infection.[ 3 ]

CONCLUSION

Clival osteomyelitis secondary to mycotic infection is a rare clinical infectious entity with a challenging diagnosis and treatment approach. It is usually considered an exclusion diagnosis and is finally confirmed with histopathological and microbiological analysis. Within the still present COVID-19 pandemic, we encourage a high suspicion of this entity to be considered in elder, diabetic patients treated with corticosteroids, with atypical signs and symptoms. Surgical debridement is not only vital part of the treatment but also part of the definite diagnosis approach.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Acknowledg ments

Translated by Rodrigo Uribe and Jafet García.

References

1. Abou-Al-Shaar H, Mulvaney GG, Alzhrani G, Gozal YM, Oakley GM, Couldwell WT. Nocardial clival osteomyelitis secondary to sphenoid sinusitis: An atypical skull base infection. Acta Neurochir (Wien). 2019. 161: 529-34

2. Balakrishnan R, Dalakoti P, Nayak DR, Pujary K, Singh R, Kumar R. Efficacy of HRCT imaging vs SPECT/CT scans in the staging of malignant external otitis. Otolaryngol Head Neck Surg. 2019. 161: 336-42

3. Baumann A, Zimmerli S, Häusler R, Caversaccio M. Invasive sphenoidal aspergillosis: Successful treatment with sphenoidotomy and voriconazole. ORL J Otorhinolaryngol Relat Spec. 2007. 69: 121-6

4. Beer-Furlan A, Balsalobre L, Vellutini EA, Stamm AC. Endoscopic endonasal approach in invasive aspergillosis of the clivus in an immunocompetent patient. Acta Neurochir (Wien). 2015. 157: 2221-2

5. Chang PC, Fischbein NJ, Holliday RA. Central skull base osteomyelitis in patients without otitis externa: Imaging findings. AJNR Am J Neuroradiol. 2003. 24: 1310-6

6. Chapman PR, Choudhary G, Singhal A. Skull base osteomyelitis: A comprehensive imaging review. AJNR Am J Neuroradiol. 2021. 42: 404-13

7. Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int J Clin Pract. 2004. 58: 74-80

8. Grey I, Arora T, Thomas J, Saneh A, Tohme P, Abi-habib R. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in english and mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier connectm, the company’s public news and information. Psychiatry Res. 2020. 14: 293

9. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020. 26: 1395-9

10. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe covid-19 converge: The perfect storm for mucormycosis. J Fungi (Basel). 2021. 7: 298

11. Johnson AK, Batra PS. Central skull base osteomyelitis: An emerging clinical entity. Laryngoscope. 2014. 124: 1083-7

12. Kurihara K. Special feature: Statistics for COVID-19 pandemic data. Jpn J Stat Data Sci. 2022. 5: 275-7

13. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003. 362: 1828-38

14. Michalowicz M, Ramanathan M. Clival osteomyelitis presenting as a skull base mass. J Neurol Surg Rep. 2017. 78: e93-5

15. Nabavizadeh SA, Vossough A, Pollock AN. Clival osteomyelitis. Pediatr Emerg Care. 2013. 29: 1030-2

16. Radhakrishnan S, Mujeeb H, Radhakrishnan C. Central skull base osteomyelitis secondary to invasive aspergillus sphenoid sinusitis presenting with isolated 12th nerve palsy. IDCases. 2020. 22: e00930

17. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021. 384: 693-704

18. Ridder GJ, Breunig C, Kaminsky J, Pfeiffer J. Central skull base osteomyelitis: New insights and implications for diagnosis and treatment. Eur Arch Otorhinolaryngol. 2015. 272: 1269-76

19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020. 395: 1054-62

Leave a Reply

Your email address will not be published.